Document is current
Any future updates will be listed below
-
Authors
Bikbov, Mukharram M.
Khalimov, Timur A.
Cerrada-Gimenez, Marc
Ragauskas, Symantas
Kalesnykas, Giedrius
Jonas, Jost B. https://orcid.org/0000-0003-2972-5227
-
Funding
Funding for this research was provided by:
Ruprecht-Karls-Universität Heidelberg
- License Information
-
More Information
Article History
Received: 6 October 2020
Accepted: 7 February 2021
First Online: 13 March 2021
Declarations
:
: Marc Cerrada-Gimenez, Symantas Ragauskas and Giedrius Kalesnykas are employees of Experimentica Ltd., Kuopio; Jost B. Jonas: Patent holder with Biocompatibles UK Ltd. (Farnham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: 20120263794); Europäische Patentanmeldung 16 720 043.5 and Patent application US 2019 0085065 A1„Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia); Patent application: Agents for use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases.
: All rabbits and guinea pigs were treated in accordance with the ARVO (The Association for Research in Vision and Ophthalmology) Statement for the Use of Animals in Ophthalmic and Vision Research.
